ArticleClinical ophthalmology (Auckland, N.Z.)2026
Retrospective Evaluation of Successive Biovance
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the clinical outcomes of serial placement of an amniotic decellularized basement membrane (DBM) graft (Biovance Methods: This retrospective study included eyes with reduced corneal sensitivity (Brill esthesiometry Levels 3-5), epithelial staining, and positive MMP-9, consistent with subclinical or Mackie Stage 1 NK. Each eye underwent serial DBM graft placement guided by clinical response over an average of 7 weeks. Corneal fluorescein staining, Brill esthesiometry, tear osmolarity, and MMP-9 status were assessed at each visit. Follow-up occurred every 1-2 weeks, with treatment advanced upon improvements in corneal staining and stabilizing biomarker trends. Outcomes included clinician-documented resolution of epithelial staining, changes in corneal sensitivity, and normalization of tear osmolarity and MMP-9. Results: A total of 936 eyes from 488 patients met enrollment criteria. Mean DBM utilization increased with disease severity (Brill 3: 3.70; Brill 4: 3.08; Brill 5: 4.30 grafts). Corneal epithelial resolution occurred in all eyes with complete follow-up. Functional corneal sensitivity improved in 0.7% of Brill 3, 31.6% of Brill 4, and 77.5% of Brill 5 eyes. Among eyes with abnormal baseline osmolarity, 70-82% normalized following treatment. MMP-9 positivity decreased across all severity groups, with 56-66% converting to negative, corresponding with improved ocular surface stability. Conclusion: Serial DBM grafting was associated with improvements in corneal staining, functional corneal sensitivity, ocular surface inflammation, and tear-film homeostasis, supporting its role in early-stage NK management. These findings suggest DBM promotes epithelial and neurosensory recovery through host-matrix interactions within the preserved basement membrane and that early intervention may help mitigate disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.